Variable gamma 9 Variable delta 2 T-cell receptor (Vgamma9Vdelta2 TCR)

The Variable gamma 9 Variable delta 2 T-cell receptor (Vgamma9Vdelta2 TCR) is the defining molecular feature of the most abundant gamma delta T-cell subset in human peripheral blood. Unlike conventional alpha-beta T cells, these cells recognize non-peptidic phosphoantigens (PAs), such as isopentenyl pyrophosphate (IPP), in a non-MHC-restricted manner (Silva-Santos et al., 2015, PMID: 25619125). This recognition process is critically dependent on the butyrophilin family proteins, specifically BTN3A1 and BTN2A1, which act as molecular sensors for intracellular PAs and present them to the Vgamma9Vdelta2 TCR (Karunakaran et al., 2020, PMID: 32327501). Once activated, these cells exhibit potent cytotoxic activity and secrete pro-inflammatory cytokines such as IFN-gamma and TNF-alpha, making them highly effective against various tumors and pathogens. In oncology, they are targeted using aminobisphosphonates like zoledronic acid to induce IPP accumulation or through novel bispecific antibodies and BTN3A1-targeting agents (e.g., ICT01) that trigger their anti-tumor response (Imcheck Therapeutics, 2024). Their unique biology allows for the development of allogeneic "off-the-shelf" therapies since they do not cause Graft-Versus-Host Disease (GvHD).

Other names

Vg9Vd2 T-cell receptorVgamma9Vdelta2-T cellGamma delta T-cell receptor subsetVγ9Vδ2 TCRPhosphoantigen-reactive T-cell receptor

Activation of Vgamma9Vdelta2 T cells via intracellular phosphoantigen accumulation (through bisphosphonates), stabilization of the BTN3A1/BTN2A1 complex (via monoclonal antibodies), or direct recruitment to tumor cells using bispecific T-cell engagers (BiTEs/Gammabodies).